Updated on 3 September 2025
Tokenization of Oncology Adjuvant and CAMs using extract from Rice
About
Keywords: Oncology adjuvant, CAMs, DeFi, Web 3.0 tokenization, Licensing, patent, IP
Our effort is to tokenize intellectual property and commercialize academic research, which allows everyone to invest in pharmaceutical projects. We acquire the license for patented Bionis, which is a joint effort of more than 10 scientists. Bionis is an active ingredient that is extracted from rice but is otherwise not available through digestion.
It will be developed as a TGA-approved oncology adjuvant and FDA-approved CAMs.
Coin holders will be allowed to redeem a coupon that can buy a full course of our product at a 35% discount.
Our oncology adjuvant has gone through animal tests. Animals taking chemotherapy usually die before they finish the whole course. Taking our Bionis will allow them to finish the therapy and extend their life. We plan to finish all the clinical tests and achieve TGA approval in about 10 years' time. Our CAMs can attain FDA approval in about 3 years' time.
Project Location
- China (Hong Kong)
Project Format
- Private Project
ESG (Environmental, Social, and Governance)
- Yes
Project Stage
- Feasibility Study Completed
Government approval on
TGA
Main Project Sector
- Technology
Technology
- Bio-Tech
- Fin-Tech
Total Project Value
- 50,000,001 USD or above
Investment Capital Required
- 2,500,001 to 5,000,000 USD
Interested Format of Cooperation
- Minority Shareholdings
Preferred Financing Model
- Open for negotiation
Previous Funding Stage
- None
Return on Investment
15% PA
Main Service(s) Required
- Financial Services
Financial Services
- Private Equity & Venture Capital
Information Technology Services
- E-payment
- Smart Card Technology
Organisation
Sydney, Australia
Similar opportunities
Project
Next-generation pulse field ablation: A world-leading innovation
- Yes
- Equity
- Bio-Tech
- Operations
- Technology
- Private Project
- Health Technology
- Medical Technology
- Financial Services
- Series C and beyond
- Minority Shareholdings
- 50,000,001 USD or above
- 10,000,001 to 25,000,000 USD
- Private Equity & Venture Capital
Shawn Fan
CEO of Ruidi Bio-tech Shanghai Subsidiary and Partner at Suzhou Mingwei Medical at Hangzhou Ruidi Bio-tech 杭州睿笛生物
Shanghai, China
Project
Carbon Credit Abatement Opportunity
- Yes
- IoT
- Mining
- Fin-Tech
- Livestock
- Oil & Gas
- Insurance
- E-payment
- Operations
- Technology
- E-Business
- Securities
- Trust Fund
- E-commerce
- IP Related
- Hedge Funds
- Data Centre
- Consultancy
- Solar Energy
- Tax Advisory
- Manufacturing
- Agro-Industry
- Biomass Energy
- Energy Storage
- Legal Advisory
- Food Processing
- Waste To Energy
- Fund Management
- Islamic Finance
- Private Banking
- Risk Management
- Public Utilities
- Syndicated Loans
- Mobile Solutions
- Urban Development
- Geothermal Energy
- Seed & Pre-Series
- Energy Management
- Wealth Management
- Big Data Solution
- Internet Services
- Power Transmission
- Financial Services
- Resource Recycling
- Commercial Banking
- Investment Banking
- Business Valuation
- Corporate Services
- Financial Advisory
- Interim Management
- Nuclear Power Plant
- Legal Due Diligence
- Hydroelectric Energy
- 500,000 USD or Below
- Open for Negotiation
- Open for negotiation
- Enterprise Solutions
- Marketing Technology
- Professional Services
- Mergers & Acquisition
- Digital Certification
- Risk Management (ITS)
- Smart Card Technology
- Other Renewable Energy
- Environmental Services
- Corporate Intelligence
- 50,000,001 USD or above
- Infrastructure Services
- Financial Due Diligence
- Irrigation And Drainage
- Fossil Fuel Power Plants
- Institutional Investment
- Environmental Engineering
- Energy and Natural Resources
- Risk Management & Resilience
- Information Technology Services
- Market Entry Strategic Analysis
- Plantation, Fishery and Forestry
- Private Equity & Venture Capital
- Public-Private Partnership Project
- Green Building Solutions & Services
- Risk Management (Financial Services)
- Transport and Logistics Infrastructure
- Environmental Management & Consultancy
- Agriculture, Food and Rural Development
- Telecommunication & Wireless Networking
TW Wes
Venture Capital Fundraising at EigenCarbon
Kowloon, China (Hong Kong)
Project
- No
- None
- Bio-Tech
- Technology
- Joint Venture
- R&D Cooperation
- Project Planning
- Health Technology
- Financial Services
- Open for Negotiation
- Open for negotiation
- Professional Services
- 1,000,001 to 2,500,000 USD
- 2,500,001 to 5,000,000 USD
- Public-Private Partnership Project
Daisy Tan
Business Development Manager at InnoHK Centre for Translational Stem Cell Biology
Hong Kong, China (Hong Kong)